Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This study is not being conducted in the United States of America (USA).
Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin
elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits T-cell
activation. These cells are involved in the inflammatory component of the disease. This study
will test the safety and efficacy of pimecrolimus cream 1% in atopic dermatitis of the face
in patients intolerant of, or dependent on, topical corticosteroids.